Revolution Medicines reported $198 million in net sales in the first five weeks after RASONQUE reached the market, according to Chief Executive Mark Goldsmith at the Jefferies Global Healthcare Conference on Monday, 16 November 2026.
Goldsmith said the early sales period was hard to read. More than 2,000 patients moved from the company's expanded access program to the commercial drug. Some late-stage patients, including some on hospice care, who had been waiting for access also contributed to the figures. Goldsmith said the company is too early in the launch to draw firm conclusions about the run rate. "The uncertainty is actually baked into the data," he said.
Management said the core stable population is expected to be second-line treatment candidates, the group studied in the RASolute 302 pivotal trial. The company has not committed to a fourth-quarter revenue preannouncement in January. It also said it will not provide a detailed breakdown of one-time versus recurring sales until the data are more stable.
Revolution Medicines said it has spent two to three years building its commercial structure. It hired commercial staff from established drugmakers, built relationships with physicians through its medical affairs team, and created the ONPath Patient Services Program to help with coverage and patient assistance. Executives said many payers have not yet placed the drug into treatment pathways.
Goldsmith said less than 2% of patients in the phase III RASolute 302 trial stopped treatment because of adverse events. Two-thirds needed no dose reduction. He called one outside report on the safety profile "total nonsense," saying it relied on a misunderstood database.
The company is pursuing frontline pancreatic cancer as a major priority. It is running multiple phase III trials in that setting, including RASONQUE alone and in combinations with chemotherapy, zoldonrasib, and PRMT5 inhibitors. Goldsmith said more than 90% of pancreatic cancers are RAS-mutated. He said the company is taking a "humble approach" because it does not yet know which combination will work best.